Abstract
Patients with schizoaffective disorder (SCA) experience complicated interplays of psychotic, depressive, and manic symptoms. Paliperidone extended-release (pali ER) tablets have been shown to be efficacious in these patients, but treatment response has not been studied relative to the onset of effects for these symptom domains. In a pooled analysis of data from two 6-week, randomized, placebo-controlled studies, the onset of treatment effects with oral pali ER was evaluated by symptom domain (psychosis, depression, mania) in patients with an acute SCA exacerbation. Subjects were categorized as having prominent psychotic (Positive and Negative Syndrome Scale score >70), depressive (Hamilton Rating Scale for Depression-21 score ≥16), or manic (Young Mania Rating Scale score ≥16) symptoms at baseline. Of the 614 patients in these analyses, 597 (97.2%), 411 (66.9%), and 488 (79.5%) had prominent psychotic, depressive, and manic symptoms at baseline, respectively. Pali ER treatment was associated with rapid and significant improvement of all three symptom domains versus placebo within 1 week of initiation, regardless of whether treatment was given as monotherapy or in combination with mood stabilizers and/or antidepressants. Adverse...Continue Reading
References
Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Dec 1, 1995·Psychiatric Services : a Journal of the American Psychiatric Association·S KentP Yellowlees
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Jul 11, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtRolf R Engel
Nov 10, 2006·Schizophrenia Research·J KaneM Eerdekens
Jan 17, 2007·Journal of Clinical Psychopharmacology·Michelle KramerMariëlle Eerdekens
May 1, 2007·Schizophrenia Research·Michael DavidsonMariëlle Eerdekens
Jul 3, 2007·Biological Psychiatry·Stephen R MarderAdam Lowy
Sep 18, 2007·Journal of Clinical Psychopharmacology·Toshi A FurukawaTeruhiko Higuchi
Jan 30, 2009·Psychiatric Services : a Journal of the American Psychiatric Association·Mark OlfsonGeorge J Wan
Mar 2, 2010·Schizophrenia Research·Carla M CanusoAmir H Kalali
May 25, 2010·The Journal of Clinical Psychiatry·Carla M CanusoNina R Schooler
Jun 23, 2010·Bipolar Disorders·Eduard VietaJoris Berwaerts
Jul 14, 2010·Journal of Affective Disorders·Joris BerwaertsDavid Hough
Sep 4, 2010·Journal of Clinical Psychopharmacology·Carla M CanusoJean-Pierre Lindenmayer
Oct 16, 2010·Journal of Affective Disorders·Joris BerwaertsDavid W Hough
Oct 20, 2010·Neuropsychiatric Disease and Treatment·Carla M CanusoCynthia A Bossie
Apr 5, 2011·The Journal of Clinical Psychiatry·David E KempJoseph R Calabrese
Mar 23, 2013·Journal of Affective Disorders·Ibrahim TurkozLarry Alphs
Jan 7, 2015·The Journal of Clinical Psychiatry·Dong-Jing FuLarry Alphs
Citations
Mar 5, 2016·Expert Opinion on Pharmacotherapy·Larry AlphsIbrahim Turkoz
Feb 1, 2017·Expert Opinion on Drug Safety·M C MauriA C Altamura
Nov 17, 2017·Expert Opinion on Pharmacotherapy·Tianmei SiYu Feng
Aug 25, 2021·CNS Drugs·Yue XuXiangrong Zhang